"Why such a big difference between 13 versus  35 for < 60,"

Because apabetalone is working to reduce MACE in patients with CKD.

"... why couldn't they spilt that more evenly like the >60 patients were split 112 verdus 114,... which was close to half & half,....?"

A better question is why is apabetalone reducing MACE so much (50% RRR) in diabetics with CKD but hardly at all in diabetics without CKD (6% RRR)?

BDAZ